ProCE Banner Activity

Phase II GEOMETRY mono-1: Capmatinib in Patients With NSCLC and High MET Amplification

Slideset Download
Conference Coverage
Capmatinib was associated with deep responses in both treatment-naive and previously treated patients with NSCLC and high-level MET amplification (GCN ≥ 10).

Released: June 04, 2020

Expiration: June 03, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Jazz Pharmaceuticals Inc

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono